Clinical Research Directory

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate * ECOG performance status 0-1 * Life expectancy ≥ 12 weeks * WBC ≥ 3,500/µL * Platelet count ≥ 100,000/µL * Hemoglobin ≥ 10.0 g/dL * Creatinine ≤ 2.0 mg/dL * Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN) * AST ≤ 2.5 times ULN * Fertile patients must use effective contraception * Willing to provide blood samples for research purposes * Able to complete questionnaire(s) alone or with assistance * Able to undergo leukapheresis * No known immunodeficiency * No other malignancy within the past 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only * No concurrent serious illness * No known history of positive PPD skin test * Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) test negative. Exclusion Criteria: * The patient was still using dexamethasone at a dose greater than 4 mg/day during mononuclear cell collection * Patients have a history of autoimmune diseases or other diseases requiring long-term use of hormones or immunosuppressive drugs * Patients with a history of allergies or allergies to immune cells and adjuvants of cellular products * Active infection with fever * Patients with neutropenia (\> 10 days) that are difficult to correct after treatment * Infection with bacteria, fungi or viruses, uncontrolled * Patients with HIV and those living with active HBV and HCV * Severe organ failure (heart, liver, kidney, lung) * Patients who had previously been treated with cell therapy products and examined by team experts deemed not suitable for treatment * Anything that researchers believe may increase the risk of subjects or interfere with test results